HSIC
HENRY SCHEIN INCEvidence as of 2026-09-03Overview · HENRY SCHEIN INC
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infe…
Management team
- Graham Stanley · VP of Investor Relations & Strategic Finance Project OfficerFind on LinkedIn
- Mr. Christopher Pendergast · Senior VP & CTOFind on LinkedIn
- Ms. Olga Timoshkina · VP of Corporate Finance, Chief Accounting Officer & Corporate ControllerFind on LinkedIn
- Mr. Michael Saul Ettinger · Executive VP & COOFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.3 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The surviving evidence presents a mixed read (+0.3 of a possible +2; was +0.3 before debate) with high confidence. Revenues rose across the comparable fiscal quarters from $ 3,168,000,000 in fiscal Q1 2025 (period ended 29 March 2025) to $ 3,458,000,000 in fiscal Q2 2026 (period ended 27 June 2026), and gross profit increased from $ 1,000,000,000 to $ 1,110,000,000 over the same span with implied gross margins moving roughly between 30.8% and 32.1%. Operating income showed limited variation, ranging from $ 151,000,000 to $ 182,000,000, while reported diluted EPS in the sample quarters was between $ 0.70 and $ 0.88. Outstanding common shares declined from 124,176,781 on 18 February 2025 to 111,446,542 as of 27 July 2026, with documented cash used for repurchases of $ 161,000,000 in the quarter ended 29 March 2025 and $ 125,000,000 in the quarter ended 28 March 2026.
Market signals are mixed but generally supportive in the sample: momentum measures are positive (momentum_3m +19.3%, momentum_6m +12.2%, momentum_12_1 +31.1% as of 2026-09-02), the price sits above key moving averages (price_vs_sma50 +3.7%, price_vs_sma200 +14.6% and a golden cross present), and volatility is low relative to the stock’s history (vol_90d_annualized +23.1%, vol_vs_own_history at the 9th percentile of 547). Valuation metrics and positioning show tension: P/FCF ttm is 287.22 on FCF ttm $ 36,000,000, P/E ttm is 27.56 on EPS ttm $ 3.28, market cap is $ 10,073,652,931 at a price of $ 90.39 with EV $ 11,031,537,931 and EV/EBITDA 11.15. Coverage and headlines skew growth- and value-oriented, with pieces calling HSIC a “Top Growth Stock for the Long-Term” and also describing it as “Cheap On Cash Flow But Fair On Earnings.”
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenue rose across the recent comparable fiscal quarters: $3,168,000,000 in fiscal Q1 2025 (period ended 29 March 2025), $3,240,000,000 in fiscal Q2 2025 (period ended 28 June 2025), $3,339,000,000 in fiscal Q3 2025 (period ended 27 September 2025), $3,368,000,000 in fiscal Q1 2026 (period ended 28 March 2026) and $3,458,000,000 in fiscal Q2 2026 (period ended 27 June 2026).
XBRL companyfacts · 0001000228-25-000025Gross profit and implied gross margins across the same quarters: fiscal Q1 2025 gross profit $1,000,000,000 (≈31.6% of $3,168M), fiscal Q2 2025 gross profit $1,016,000,000 (≈31.4% of $3,240M), fiscal Q3 2025 gross profit $1,026,000,000 (≈30.8% of $3,339M), fiscal Q1 2026 gross profit $1,070,000,000 (≈31.8% of $3,368M), and fiscal Q2 2026 gross profit $1,110,000,000 (≈32.1% of $3,458M).
XBRL companyfacts · 0001000228-25-000025Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Nothing in this slice of the evidence rose to a claim — a quiet read, which itself is information.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Momentum measures are positive: momentum_3m is +19.3%, momentum_6m is +12.2%, and momentum_12_1 is +31.1% as of 2026-09-02.
Moneyta signal set · 2026-09-02weakened in debatePrice is above key moving averages: price_vs_sma50 is +3.7% and price_vs_sma200 is +14.6%, and a golden_cross is present as of 2026-09-02.
Moneyta signal set · 2026-09-02Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02, HENRY SCHEIN INC (HSIC) is a holding in the IVV ETF at 0.01% weight of the fund.
ETF constituents · market dataThere are no insider Form 4 filing events in the provided evidence.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
A growth-oriented positive framing appears in a headline calling Henry Schein a “Top Growth Stock for the Long-Term.”
News · zacks.com · 2026-09-02Several headlines frame Henry Schein as potentially undervalued or offering upside (headlines asking if HSIC is "Undervalued Right Now" and whether "more upside still [is] available").
News · zacks.com · 2026-09-02Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The market price used in this analysis implies an annual free cash flow (FCF) growth rate of 91.45% for the business under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve-month price-to-free-cash-flow (P/FCF) is 287.22, with FCF ttm of $36,000,000 and FCF per share of $0.3147.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several company-specific fundamentals point toward a constructive read: sequential revenue gains across comparable fiscal quarters (fundamentals-0) accompanied by modestly improving gross margins (fundamentals-1) and a consistent share-count reduction via repurchases (fundamentals-4, fundamentals-5) which can lift per-share metrics. Market signals show positive momentum and a price sitting above key moving averages with a recent golden cross (market-0, market-1), while low beta and low realized volatility versus the stock’s history indicate the move has occurred with relatively muted price swings (market-4, market-2). News coverage is largely company-specific and frames valuation/growth opportunity narratives rather than attributing strength to broad market forces (news-4, news-0–news-3). The valuation headwinds (valuation-0, valuation-1) are the clearest counterpoint, but their strength is weakened by the thin trailing free-cash-flow base and the material share count decline that increases per-share metrics—together these facts suggest the negative valuation signals merit cautious interpretation alongside the stronger operating and market evidence.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.34
25 surviving claims rest on 12 distinct sources; the heaviest analyst carries 24% of them, and 98% of what the desk raised survived the debate.
The dataset spans a moderate diversity of sources (12) but a relatively small surviving claim set; this means the read has some breadth but not extensive independent corroboration. One analyst contributes nearly a quarter of surviving claims and the debate eliminated very little (98% survival), which raises the possibility that desk consensus reinforced initial views rather than heavily stress-testing them — treat the synthesis as informational but assign limited confidence to claims that lack multiple independent confirmations.
Peer context · computed, not argued
12-1 momentum ranks 1st of 2 in Medical Distribution (as of 2026-09-02).
90-day volatility ranks 2nd of 2 in Medical Distribution (as of 2026-09-02).
dividend yield ranks 2nd of 2 in Medical Distribution (as of 2026-09-02).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
13 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.7 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.3 to the score
1 holdings record
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on HSIC Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.